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Objective: To document the experience of one referral service with patients diagnosed with
Evans syndrome, the treatment and response and to brieﬂy review current treatment strate-
gies  and results.
Methods: Patients enrolled in this study fulﬁlled criteria for Evans syndrome. Data were
retrieved from the clinical ﬁles and electronic databases of the Department of Hematology,
Hospital Universitario “Dr. José Eleuterio González”. Treatment modalities and response and
the  use of additional therapies were evaluated. The literature was reviewed in the context
of  the clinical course of the studied patients.
Results: Six patients were diagnosed with Evans syndrome in the study period. Patient 1 was
treated with steroids, relapsed twice and was again treated with steroids. Patient 2 treated
initially with steroids plus intravenous immunoglobulin was subsequently lost to follow-up.
A  good response was achieved in Patients 3 and 4, who were treated with steroids plus ritux-
imab; patient 4 also received danazol as a second-line therapy. However both relapsed and
subsequently underwent splenectomy at ten and nine months, respectively. One patient,
number 5, treated with steroids, danazol and rituximab did not relapse within four years
of  follow-up and Patient 6, who received steroids plus danazol did not relapse within three
years of follow-up.
Conclusion: Evans syndrome is an uncommon hematologic condition rarely diagnosed and
not  widely studied. Clinicians must have it in mind when evaluating a patient with a positive
direct antiglobulin test, anemia and thrombocytopenia, since prognosis depends on its early
recognition and opportune therapy, but even this leads to variable results.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Hospital Universitario Dr. José E. González, E
Colonia  Mitras, Centro, 64460 Monterrey, NL, Mexico.
E-mail address: carjaime@hotmail.com (J.C. Jaime-Pérez).
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vans syndrome is a rare autoimmune disorder character-
zed by simultaneous or sequential presence of a positive
nti-globulin test, autoimmune hemolytic anemia (AIHA) and
mmune thrombocytopenia (ITP).1 It is characterized by fre-
uent exacerbations and remissions within a chronic course.
vans syndrome was ﬁrst described in 19512 and it is recog-
ized as a poor prognostic factor in autoimmune cytopenias.3
t is a rare disorder diagnosed in 0.8% to 3.7% of all AIHA or ITP
ases.1 Its etiology and cause are unknown, but alterations in
mmune regulation mechanisms are documented.
This syndrome can be classiﬁed as primary or idiopathic
hen there is no associated disease, and secondary when it is
ssociated with other autoimmune diseases, such as systemic
upus erythematosus (SLE), primary antiphospholipid syn-
rome, Sjögren syndrome, IgA deﬁciency, Hodgkin’s disease
nd chronic lymphocytic leukemia.4 The diagnosis is made by
xclusion of other pathologies, including infectious processes
nd malignant and autoimmune diseases. It presents with
icytopenia, which can coincide or occur separately or sequen-
ially. After the appearance of the ﬁrst cytopenia, the second
ay occur months to years later, which can delay diagnosis.5,6
Management of Evans syndrome remains a challenge.
esponse to treatment varies even within the same individ-
al. Indications for treatment have not been established by
vidence-based studies,5 in part due to the low frequency
nd heterogeneous nature of the disease. The ﬁrst-line treat-
ent for Evans syndrome is corticosteroids with or without
ntravenous immunoglobulin (IVIG).7 The range of options for
econd-line treatment includes immunosuppressive agents,
he monoclonal antibody rituximab, chemotherapy or a com-
ination of these agents. However, only a small percentage
f patients achieve complete remission and these drugs have
umerous side effects.8 Splenectomy may also be considered
 second-line treatment. The majority of patients will respond
o ﬁrst or second-line therapy modalities, sometimes for sev-
ral years. However, for patients with severe relapsing disease
espite second-line therapy, other options have to be con-
idered. The main third-line options are cyclophosphamide,
lemtuzumab or stem cell transplantation.5
There is very limited information available in the literature
egarding this infrequent syndrome; therefore we decided to
resent and discuss six cases diagnosed in our hospital over
ix years in order to call the attention of the physician to the
mportance of considering this disease when confronted with
 patient exhibiting clinical and laboratory features compati-
le with Evans syndrome.
ethods
his study was performed in accordance with the ethical stan-
ards of the Helsinki Declaration, including the provisions for
atient informed consent. The Review and Ethics Committee
f the institution approved the study.
The six patients included in this report were diagnosed
etween 2007 and 2012. All patients presented with AIHA
nd a positive direct antiglobulin test plus ITP. Clinical 1 5;3  7(4):230–235 231
presentation included the usual features of hemolytic ane-
mia: pallor, lethargy, jaundice, thrombocytopenia, petechiae,
bruising and mucocutaneous bleeding.
There are no guidelines established for management of
Evans syndrome, thus, for the purpose of this report, response
was deﬁned as resolution of all clinical symptoms and
increase or no further decrease in both, platelet count and
hemoglobin concentration. Relapse was considered to exist
when patients presented with the same or similar clinical
symptoms and laboratory data, including a positive direct
antiglobulin test.
Results
Patient  characteristics
Data of six patients, four women (66.64%) and two  men
(33.32%), fulﬁlling the diagnostic criteria of Evans Syndrome
were retrieved from the clinical ﬁles and electronic databases
(Table 1). Median age at diagnosis was 24 years. Both cytope-
nias occurred simultaneously in all cases. No cases of
autoimmune neutropenia at diagnosis or during the clinical
course were observed. Evans syndrome was considered idio-
pathic in one patient (16.6%) and was associated with one or
more  underlying diseases in the other ﬁve patients (83.4%;
Table 1).
The complete blood count at diagnosis showed remarkable
alterations (Table 2), including platelet counts ranging from
2.33 to 13.1 × 109/L (median: 5.8 × 109/L); hemoglobin concen-
tration at presentation varied from 6.1 to 10.7 g/dL (median:
6.9 g/dL), the Mean corpuscular volume was within the nor-
mal  range (76.2 to 101 fL), but the red cell distribution width
varied widely from 17.1 to 25.6% (median: 20%) reﬂecting
the abundant presence of reticulocytes which ranged from
6.8 to 23.1% (median: 9.8%). Accordingly, indirect bilirubin
concentration was increased in almost every case (median:
1.5 mg/dL), and lactate dehydrogenase (LDH) values varied
between 295 and 554 U/L (median: 426.5 U/L), reﬂecting the
ongoing active hemolysis. The presence of anemia at vari-
able degrees with hemolytic characteristics, including a high
level of LDH and/or indirect bilirubin, with a repeatedly posi-
tive direct antiglobulin test and thrombocytopenia led to the
diagnosis of Evans syndrome in all six patients.
Detailed information regarding clinical presentation, treat-
ment and evolution, as well as relapses and their therapy is
shown in Table 3. Patient 1 was the only case in which steroids
were successfully used as both ﬁrst-line treatment and during
relapses without additional medications; in all the remaining
ﬁve cases a combination of therapies was needed to achieve
response. Response times, as days needed for the increase in
hemoglobin concentration and platelet count to take place,
are shown in Table 3. Patients were discharged at a median of
nine days (range: 3–12 days).
Follow-up  and  relapsesRelapse was diagnosed when patients presented with same
or similar symptoms as baseline and the simultaneous
or sequential presence of a positive anti-globulin test,
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Table 1 – General characteristics of six patients diagnosed with Evans syndrome.
Patient Gender Age Date of diagnosis Medical history before diagnosis
1 F 10 2007 Chronic ITP since age 4, treated with steroids
2 F 14 2011 SLE, ITP since age 10, treated with steroids
3 F 42 2009 SLE, AIHA
4 F 19 2010 SLE
5 M 29 2011 None
6 M 29 2012 SLE, APLA, PTT prolongued
ITP: immune thrombocytopenia; SLE: systemic lupus erythematosus; AIHA: autoimmune hemolytic anemia; PTT: partial thromboplastin time;
APLA: antiphospholipid antibody.
Table 2 – Laboratory results at diagnosis of six patients with Evans syndrome.
Patient 1 2 3 4 5 6
Platelet count (× 109/L) 8.26 3.47 13.1 9.37 2.33 3.12
Hemoglobin (g/dL) 10.7 7.18 6.37 6.58 6.09 10.5
Hematocrit (%) 33.6 22.3 18.4 19.0 18.4 31.9
MCV (fL) 76.2 81.7 101.0 88.9 86.9 78.7
RDW (%) 20.2 19.8 25.6 23.6 17.1 18.9
WBC (× 109/L) 3.37 4.69 7.92 12.0 12.5 11.9
Neutrophil count (× 109/L) 2.79 3.73 4.98 9.01 11.5 9.06
Lymphocyte (× 109/L) 0.489 0.76 2.06 2.16 0.74 1.85
Reticulocyte (%) 7.6 6.8 23.1 9.8 9.8 10.0
Total bilirubin (mg/dL) 1.87 1.8 3.41 1.41 1.85 0.9
Direct bilirubin (mg/dL) 0.25 0.32 0.61 0.23 0.33 0.2
Indirect bilirubin (mg/mL) 1.7 1.5 2.8 1.2 1.5 0.7
Lactate dehydrogenase (IU/L) 368 295 554 378 475 487
BC: wMCV: mean corpuscular volume; RDW: red cell distribution width; W
autoimmune hemolytic anemia and immune thrombocyto-
penia. An appropriate follow-up was documented in ﬁve of
the six patients. Three patients relapsed within nine months
to ﬁve years.
One patient (Patient 2) responded satisfactorily to ini-
tial steroid therapy and was subsequently lost to follow-up.
Two patients, 5 and 6, had not relapsed 45 and 32 months
after the initial diagnosis, respectively. Patients 1, 3, and 4
relapsed. Patient 1 presented two relapses, the ﬁrst one, ﬁve
years after diagnosis, was treated with steroids, obtaining
complete remission until a year later when she presented
moderate thrombocytopenia and severe AIHA. This episode
was again treated as in her ﬁrst relapse, with steroids, obtain-
ing a third remission lasting 24 months to date. Patient 3 had
a relapse at ten months after diagnosis; she was treated with
dexamethasone, prednisone and rituximab, with no response;
splenectomy was performed at this time. This patient has
not relapsed to date, 57 months after splenectomy. Patient 4
relapsed at nine months. She was treated with splenectomy
and has not suffered further relapse 32 months after removal
of the spleen; clinical course and therapy for these ﬁve patients
are summarized in Table 3.
DiscussionEvans syndrome is a rare autoimmune regulation disorder
whose exact pathophysiology is unknown. Clinically, the dis-
ease consists of simultaneous or sequential autoimmune
hemolytic anemia and immune thrombocytopenia, with orhite blood cell count.
without bleeding from mucous membranes and petechiae,
and/or immune neutropenia in the absence of any other
cause.1
There is a decrease in serum immunoglobulins, especially
IgG, IgM and IgA.9 Savasan et al.4 described evidence of lym-
phoid hyperplasia and hyperactivity with deregulation of the
APO-1 antigen, which is expressed on activated T and B cells,
and is in intimate relationship with the immune pathway
inducing apoptosis. Wang et al.9 showed proportions of dimin-
ished T4 and increased T8 cells with a decreased T4:T8 index.
Decreases in the production of interleukin-10 and gamma-
interferon have been reported, and it is postulated that this
causes the activation of B cells producing auto-antibodies.
These alterations are not exclusive to Evans syndrome as they
can be found in other immune diseases, thus it remains to be
established if they are indeed a cause of the disease or merely
associated immune phenomena.
The differential diagnoses for Evans syndrome include
thrombotic thrombocytopenic purpura, chronic cold agglu-
tinin disease, other causes of acquired or hereditary hemolytic
anemia, and drug-induced hemolytic anemia and/or thrombo-
cytopenia. Its exact incidence remains unknown. In a review of
adult patients with immunocytopenias including 766 patients
with 399 cases of AIHA and 367 cases of thrombocytopenia,
Evans syndrome was diagnosed in only six (0.78%) patients.10
The largest reported series of Evans syndrome in pediatric
patients included 164 cases of ITP and 15 of AIHA; only seven
(4.1%) children were diagnosed with the syndrome.11
Evans syndrome can be grouped into primary or idio-
pathic, when there is no associated autoimmune disease and
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Table 3 – Clinical presentation, treatment, and relapse of six patients diagnosed with Evans syndrome.
# Clinical presentation Treatment Response time after
ﬁrst-line treatment
(days)
PLT (109/L) Hb (g/dL) Relapse C.P. of relapse Treatment after
relapse
1 Generalized petechiae,
ecchymosis
1st  Dexamethasone 8 152 11.2 Twice 5 years Choluria,
jaundice, pallor
Steroids
2 Ecchymosis, gingivorrhagia,
epistaxis, petechiae, pallor,
jaundice
1st
Methylprednisolone + IVIG
10 71 10.5 No – –
3 Gingival bleeding, epistaxis,
fatigue, weakness, dyspnea
1st Dexametha-
sone + Prednisone
2nd Rituximab
10  34.5 8.9 10 months Gingival
bleeding,
epistaxis, fatigue,
weakness,
dyspnea
Splenectomy
4 Generalized petechiae,
gingivorrhagia, pallor,
fatigue, weakness,
jaundice, and syncope
1st Dexamethasone
2nd Rituximab + Danazol
7  59.7 8.51 9 months Transvaginal
bleeding, anemic
syndrome
Splenectomy
5 Petechiae, ecchymosis,
epistaxis, gingivorrhagia,
Anemic syndrome
1st  Dexamethasone
2nd Danazol + Rituximab
8  11 8 No – –
6 Petechiae, ecchymosis,
epistaxis
1st  Dexamethasone
2nd Danazol
10  57.3 11.3 No – –
PLT: platelet count; Hb: hemoglobin; C.P.: clinical presentation; IVIG: intravenous immunoglobulin.
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secondary when it is associated with another autoimmune
disease, such as SLE, Sjögren syndrome, Hodgkin’s disease,
or chronic lymphocytic leukemia, among others.4 In adults,
an underlying cause can be expected in 70% of the cases.12
In our study ﬁve of six patients had an autoimmune disease
diagnosed before they developed Evans syndrome.
The disease is characterized by frequent exacerbations and
remissions within a chronic course and response to treatment
varies even within the same individual.5 Most patients require
treatment although occasional spontaneous remissions have
been reported, as was the case in one of 42 patients.13 Indi-
cations for treatment have not been established by other
evidence-based studies. However, it is reasonable and usual
to treat symptomatic patients with low blood counts; not
all asymptomatic patients with low counts require treat-
ment and the decision to treat or not should be considered
according to each individual case.5 Most of the data are anec-
dotal and inconclusive with difﬁcult interpretation because of
the concomitant use of corticosteroids and other treatment
modalities.13,14
Corticosteroids remain the mainstay of therapy for con-
trol of the acute symptomatic cytopenias, with good initial
results, despite lack of controlled trials demonstrating their
efﬁcacy.5 Pui et al., on describing the clinical features and long-
term follow-up of seven children with Evans syndrome, found
that in all six children requiring treatment, prednisolone at a
daily dose of 1–2 mg/kg resulted in remission; however, this
response was lost upon dose reduction and/or during acute
viral infections.11 In the current study, all six patients were
treated with at least one corticosteroid. The initial dose of
methylprednisolone (1.0 g IV diluted in 100 mL, every 24 h for
four doses) was used only for Patient 2. The treatment strategy
for Patient 3 was prednisone administered at a dose of 40 mg
p.o. every 12 h until reaching a response or for four weeks.
When using dexamethasone, as was the case in ﬁve of the
six patients in this study, the dose was 40 mg IV every 24 h
for four doses, with this obtaining a good clinical response in
all cases, with improvement in platelet count and hemoglobin
concentration but without reaching normalization.
If steroids are ineffective or unacceptably high doses are
required to maintain remission or if toxicity occurs, the
most commonly used treatment is IVIG. Various doses have
been suggested, most commonly 0.4 g/kg/day for four doses
with some other authors recommending higher doses (up to
5.0 g/kg) to improve response in AIHA.15 In our patients, only
one received IVIG as part of her initial treatment (Patient 2) at
a single dose of 1.0 g/kg with good response.
Second-line treatment includes immunosuppressive
agents (cyclosporine and mycophenolate mofetil), chemother-
apy (vincristine and cyclophosphamide), danazol and
monoclonal antibodies (rituximab and alemtuzumab).5
Although splenectomy has traditionally been used as initial
second-line therapy in patients with autoimmune cytope-
nia (ITP or AIHA) who did not respond to or relapsed after
standard therapy with steroids with or without IVIG, the role
of splenectomy in the treatment of Evans syndrome is not
5clearly established. Overall, the response rate to splenectomy
is lower than the 70–75% reported in chronic ITP. There are
few data for Evans syndrome; thus accurate response rates
cannot be cited.16 Splenectomy often produces immediate 2 0 1 5;3  7(4):230–235
improvement or even complete normalization of blood
counts. This response is often transient and relapse occurs in
most cases 1–2 months post-splenectomy independently of
whether steroids are continued postoperatively.11,13,14 How-
ever, splenectomy occasionally results in sustained remission
(one of eight patients remained in complete remission at six
years post-splenectomy in one report),15 and there is some
evidence that splenectomy may be beneﬁcial in reducing
the frequency of relapses and lowering the maintenance
dose of steroids.11,13,14 Only two patients in our group were
splenectomized (Patients 3 and 4) due to relapse.
Danazol was administrated in three out of six patients in
combination with steroids. These three individuals had good
initial responses; however, two relapsed and required addi-
tional treatment with one being successfully splenectomized
(Patient 4) after the ﬁrst relapse. On the other hand, ritux-
imab at a dose of 375 mg/m2 was used in three of six patients,
with no response in two patients (Patients 3 and 4), leading to
splenectomy. Only one patient (Patient 5) responded satisfac-
torily to rituximab.
The majority of patients will respond to ﬁrst or second-line
therapy, and this response can last several years. However,
for patients with severe, relapsing disease despite second-
line therapy, other options have to be considered. The main
third-line options are cyclophosphamide, alemtuzumab or
stem cell transplantation.5 Three of the patients in this study
relapsed within nine months to ﬁve years, however none of
them required a third-line treatment. This wide variability
and unpredictability in relapsing times have been reported
previously.13,14
There are important issues to deﬁne with respect to treat-
ment and response criteria for Evans syndrome. In this regard
it is not clear whether it is important for steroids to be admin-
istered at the same time as IVIG, although this is common
practice. The majority of patients, unfortunately, relapse as
therapy is tailed off and second-line therapy will be required.
The choice of which second-line agent to use depends upon
clinical criteria, particularly the age of the patient, severity
of the disease and its natural history because all of these
treatments have signiﬁcant short- and long-term side effects.5
It is pertinent to underscore that there are no standard-
ized response criteria for Evans syndrome, in contrast to ITP
where an increase in the platelet count to ≥30.0 × 109/L is
considered as response (R) and ≥100.0 × 109/L on at least two
separate occasions at least seven days apart as a complete
response.17
Our six patients presented with severe clinical manifesta-
tions and received steroids with or without IVIG, danazol or
rituximab in order to prevent or delay complications that can
endanger life.18 After failure of rituximab, splenectomy was
performed in two of three relapsing patients, underscoring
the importance of this intervention in the management of the
disease, and suggesting that, at least in the setting of autoim-
mune associated Evans syndrome, the addition of rituximab
does not guarantee therapeutic success.
For an early diagnosis and successful treatment, Evans syn-
drome must be kept in mind whenever hemolytic anemia
with a positive direct antiglobulin test and thrombocytopenia
are present, especially in patients with an autoimmune dis-
ease.
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